Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Novavax, Inc.NASDAQ: NVAX

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns negative

Q1 FY2026 other non-cash items was -$8.71M, compared with $16.83M a year earlier. Trailing-twelve-month other non-cash items was $113.61M. Over 3 fiscal years it compounded at -32.1% a year.

Context

  • Other non-cash items amounted to 12.4% of revenue in FY2025, up 5.8 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other non-cash items holds near -$8.71M or moves back toward the trailing-twelve-month quarterly average of $28.4M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.71M-341.3% QoQ
Last fiscal yearDec 2025
$139.14M+409.9% YoY
LTMMar 2026
$113.61M+433.2% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-151.7%——
1 year+409.9%——
3-year CAGR-32.1%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
139.14M USD
Year-over-year change
+409.9%
4-year CAGR
+0.4%

Other Non-Cash Items vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +433.2% is the 2nd highest of 8, against a peer median of +119.5%.
  • Other non-cash items amounts to 19.1% of revenue for NVAX, versus a peer median of 8.4%.
NVAX Competitors
Other Non-Cash Items for NVAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€491.35M EUR+224.1%—18.6%
MRNAModerna, Inc.LTM Sep 2026$213M USD+373.3%—8.4%
NVAXNovavax, Inc.LTM Mar 2026$113.61M USD+433.2%-32.1%19.1%
VALNValneva SELTM Mar 2026€46.24M EUR+65.5%-3.1%29.6%
EBSEmergent BioSolutions Inc.LTM Mar 2026$28.7M USD-1.0%+17.8%4.2%
PCVXVaxcyte, Inc.LTM Jun 2026$8.46M USD+115.3%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.66M USD+505.4%-9.4%5.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$1.5M USD+119.5%——
Peer median (excluding NVAX) —+119.5%-3.1%8.4%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
Deferred Income Tax00000
Stock-Based Compensation183.63M130.3M85.36M48.15M36.02M
Change in Working Capital1.73B(361.15M)(376.84M)48.48M(887.71M)
Accounts Receivables(192.27M)249.17M(274.44M)354.09M61.04M
Inventory(600.33M)(477.8M)(74.46M)12.91M(3.24M)
Accounts Payables600.33M913.4M(378.81M)(385.63M)(322.57M)
Other Working Capital1.93B(1.05B)350.87M67.11M(622.94M)
Other Non-Cash Items136.79M443.8M81.35M(44.89M)139.14M
Operating Cash Flow322.95M(415.94M)(713.97M)(87.26M)(244.64M)
Capital Expenditures(57.49M)(92.99M)(58.81M)(13.06M)(5.56M)
Acquisitions (Net)57.49M00192.64M0
Purchases of Investments(2.17M)00(825.59M)(445.27M)
Sales of Investments159.81M00443.55M353.74M
Other Investing Activities(57.49M)00018.83M
Investing Cash Flow100.15M(92.99M)(58.81M)(204.04M)(78.27M)
Debt Repayment(127.91M)81.66M(352.35M)(3.99M)32.53M
Common Stock Issued564.86M249.23M360.24M263.27M0
Common Stock Repurchased0000(4.8M)
Dividends Paid00000
Other Financing Activities24.76M(5.9M)(3.59M)1.31M0
Financing Cash Flow461.71M324.99M4.47M260.58M27.74M
Effect of Forex Changes(5.29M)4.52M3.27M(7.8M)5.93M
Net Change in Cash879.52M(179.41M)(765.04M)(38.52M)(289.24M)
Free Cash Flow265.46M(508.92M)(772.77M)(100.32M)(250.2M)

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.